子宫动脉栓塞与高强度聚焦超声消融治疗症状性子宫肌瘤的系统评价与Meta分析
该研究对比子宫动脉栓塞(UAE)与高强度聚焦超声(HIFU)消融治疗症状性子宫肌瘤的临床效果。纳入7篇文章(5项试验)、4592名女性。UAE组症状评分下降更多、生活质量提升更高,再干预率更低,但妊娠率显著低于HIFU组;不良事件发生率两组无统计学差异。
要点
- 与HIFU消融相比,UAE治疗症状性子宫肌瘤的症状缓解和生活质量改善更显著。
- UAE组术后再干预率显著低于HIFU组(RR 0.25)。
- UAE组妊娠率显著低于HIFU组(RR 0.06),但受混杂因素影响不能断言HIFU更利于妊娠。
核心结论
- 与HIFU消融相比,UAE对症状性子宫肌瘤的症状缓解和生质量改善更显著,再干预率更低,但妊娠率也更低。
- 因混杂因素,不能得出HIFU消融比UAE更有利于期望妊娠的结论。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、EMBASE、Web of Science、Cochrane Library、Google Scholar和ClinicalTrials.gov,时间范围2000年1月至2020年8月。
- 纳入比较UAE与HIFU消融治疗子宫肌瘤临床结局的对照研究,最终纳入7篇文章(5项试验),共4592名症状性子宫肌瘤女性。
- 系统评价注册号CRD42020199630,两位研究者独立筛选文献并评估偏倚风险。
主要发现
- UAE组随访时子宫肌瘤症状评分下降幅度高于HIFU组,总体均数差19.54(95%CI 15.21-23.87;p<.001)。
- UAE组生活质量评分提升幅度高于HIFU组,总体均数差15.72(95%CI 8.30-23.13;p<.001)。
- UAE组再干预率显著低于HIFU组,RR 0.25(95%CI 0.15-0.42;p<.001)。
- UAE组妊娠率显著低于HIFU组,RR 0.06(95%CI 0.01-0.45;p=.006)。
- 两组不良事件发生率差异无统计学意义(p=.53)。
关键数值与推荐
- 症状评分下降均数差19.54(95%CI 15.21-23.87;p<.001),UAE优于HIFU。
- 生活质量评分提升均数差15.72(95%CI 8.30-23.13;p<.001),UAE优于HIFU。
- 再干预率RR 0.25(95%CI 0.15-0.42;p<.001),UAE低于HIFU。
- 妊娠率RR 0.06(95%CI 0.01-0.45;p=.006),UAE低于HIFU。
- 不良事件发生率组间差异p=.53,无统计学意义。
临床怎么用
- 对有症状子宫肌瘤患者,UAE在症状缓解、生活质量改善和降低再干预率方面可能优于HIFU消融。
- 对有妊娠需求的患者,选择UAE需谨慎评估,因其妊娠率显著低于HIFU组,但HIFU是否更有利妊娠尚无定论。
- 两组不良事件发生率无显著差异,安全性需结合个体情况综合判断。
局限性
- 纳入研究数量有限(7篇文章、5项试验),可能影响结果稳健性。
- 妊娠率比较受混杂因素影响,不能据此推断HIFU更利于妊娠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to compare the clinical effects of uterine artery embolization (UAE) with those of high-intensity focused ultrasound (HIFU) ablation for the treatment of symptomatic uterine myomas. DATA SOURCES: We searched PubMed, EMBASE, Web of Science, Cochrane Library, Google Scholar, and ClinicalTrials.gov for studies from January 2000 to August 2020. Related articles and relevant references of the included studies were also searched. METHODS OF STUDY SELECTION: Two researchers independently performed the data selection. We included comparative studies that compared the clinical outcomes of UAE with those of HIFU ablation in women with myomas. TABULATION, INTEGRATION, AND RESULTS: We assessed the study quality using the Cochrane Handbook for Systematic Reviews of Interventions for evaluating the risk of bias. Two independent researchers performed the article selection according to the screening criteria and rated the quality of evidence for each article. We calculated pooled mean difference with 95% confidence interval (CI) for continuous data and relative risk (RR) with 95% CI for dichotomous data. The systematic review registration number is CRD42020199630 on the International Prospective Register of Systematic Reviews. A total of 7 articles (5 trials), involving 4592 women with symptomatic uterine myomas, were included in the meta-analysis. Compared with the HIFU ablation group, the decrease in "uterine fibroid symptom" scores as well as the increase in quality-of-life scores at the time of follow-up were higher in the UAE group, with overall mean difference 19.54 (95% CI, 15.21-23.87; p <.001) and 15.72 (95% CI, 8.30-23.13; p <.001), respectively. The women in the UAE group had a significantly lower reintervention rate (RR 0.25; 95% CI, 0.15-0.42; p <.001). The women undergoing UAE had a significantly lower pregnancy rate than those undergoing HIFU ablation (RR 0.06; 95% CI, 0.01-0.45; p = .006). The difference in the incidence of adverse events between the 2 groups was not statistically significant (p = .53). CONCLUSION: Compared with HIFU ablation, UAE provided more significant alleviation of symptoms and improvement in quality of life, lower postoperative reintervention rate, and lower pregnancy rate for women with uterine myomas. However, we cannot conclude that HIFU ablation is more favorable for desired pregnancy than UAE because of the confounding factors.
引用
- Liu L, Wang T, Lei B, et al. Uterine Artery Embolization Compared with High-intensity Focused Ultrasound Ablation for the Treatment of Symptomatic Uterine Myomas: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2020. PMID: 33197612. doi:10.1016/j.jmig.2020.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。